针灸与免疫检查点抑制剂治疗非小细胞肺癌应答的关联
该回顾性研究纳入217例接受免疫检查点抑制剂(ICI)治疗的非小细胞肺癌(NSCLC)患者,以总体人群中位无进展生存期(mPFS 8.87个月)前开始针灸者定义为针灸组(n=97)。结果显示针灸与mPFS改善显著相关(10.23 vs 7.87个月,P=0.036),骨转移患者获益明显,但PD-L1阳性亚组未见改善趋势。
要点
- 针灸与ICI治疗NSCLC患者mPFS改善显著相关。
- 骨转移患者针灸组进展风险降低76%,死亡风险降低53%。
- PD-L1阳性亚组未见针灸改善趋势,需生物标志物分层。
核心结论
- 针灸与ICI治疗NSCLC患者预后改善正相关,尤其在骨转移患者中。
- 将针灸整合入肿瘤治疗需生物标志物指导的患者分层。
研究设计与样本
- 回顾性分析217例接受ICI治疗的NSCLC患者。
- 在总体人群mPFS(8.87个月)前开始针灸者归为针灸组(n=97)。
- 采用Cox回归、倾向性评分匹配(PSM)、亚组和交互分析。
主要发现
- 针灸与mPFS改善显著相关(10.23 vs 7.87个月,P=0.036)。
- 总生存有数值趋势但未达统计学显著(mOS 24.1 vs 20.9个月,P=0.352)。
- 骨转移患者针灸组进展风险降低76%(HR=0.24,95%CI 0.14-0.42,P<0.001),死亡风险降低53%(HR=0.47,95%CI 0.21-1.03,P=0.049)。
- PD-L1阳性亚组无改善趋势(亚组HR>1.0),交互HR>2.0提示可能削弱ICI疗效。
- PSM后针灸仍独立关联PFS改善(aHR=0.62,95%CI 0.41-0.94,P=0.024)。
临床怎么用
- 对ICI治疗的NSCLC患者,尤其骨转移者,可考虑联合针灸以改善PFS。
- PD-L1阳性患者联合针灸需谨慎评估,避免潜在疗效削弱。
局限性
- 回顾性设计可能存在选择偏倚,尽管采用PSM缓解。
- 针灸组定义基于mPFS时间点,可能引入时序偏倚。
- 总生存差异未达统计学显著,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment, yet low response rates and resistance remain challenges. Emerging evidence suggests acupuncture may enhance ICI effectiveness by reprogramming immunosuppressive tumor microenvironments. METHODS: A retrospective analysis was conducted on 217 ICI-treated NSCLC patients. Patients who initiated acupuncture before median progression-free survival (mPFS, 8.87 months) of the overall population were classified as the acupuncture group (n = 97). Cox regression analysis was employed to evaluate the association between clinical characteristics and outcomes. Propensity score matching (PSM) was performed to mitigate selection bias. Subgroup and interaction analyses were conducted to evaluate potential effect modifiers. RESULTS: Acupuncture was significantly associated with improved mPFS (10.23 vs. 7.87 months, P = 0.036), while a numerical trend favoring acupuncture was observed in overall survival (mOS: 24.1 vs. 20.9 months, P = 0.352). Obvious benefits emerged in bone metastasis patients, with the acupuncture group reducing progression risk by 76% (HR = 0.24, 95% CI 0.14-0.42, P < 0.001) and death risk by 53% (HR = 0.47, 95% CI 0.21-1.03, P = 0.049). Conversely, PD-L1-positive subgroups exhibited no trend of improvement (subgroup HR > 1.0), with interaction HRs > 2.0 indicating potential impairment of ICI efficacy. The results of post-PSM data suggest that acupuncture was independently associated with improved PFS (aHR = 0.62, 95% CI 0.41-0.94, P = 0.024). CONCLUSION: Our findings suggest a positive association between acupuncture and improved outcomes in ICI-treated NSCLC patients, particularly in those with bone metastasis, underscoring the potential role of acupuncture in the integrative management of cancer. However, biomarker-guided patient stratification is essential for integrating acupuncture into oncology care.
引用
- Zhou R, Zhu YJ, He YH, et al. The association between acupuncture and response to immune checkpoint inhibitors in non-small cell lung cancer. Chin Med. 2025. PMID: 40973957. doi:10.1186/s13020-025-01148-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。